Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Safety Culture Clashes Continue At FDA, Despite Reform Efforts

Executive Summary

FDA's efforts to improve communications between the Office of New Drugs and the Office of Surveillance and Epidemiology may need to be enhanced, based on a confrontation between OND staff and OSE Associate Director for Science and Medicine David Graham during an April 12 meeting of FDA's Arthritis Drugs Advisory Committee concerning Merck's COX-2 inhibitor Arcoxia. The agency has been touting its ongoing efforts to improve internal communication processes after an Institute of Medicine report on FDA's drug safety oversight expressed concern about cultural conflicts between the agency's new product review and postmarket safety oversight units (1"The Pink Sheet" Feb. 12, 2007, p. 17).

You may also be interested in...



FDA Hires Consultants To Ease Conflicts Between CDER Staff

FDA is bringing in outside consultants to help improve staff interactions and build leadership in the agency's Center for Drug Evaluation and Research

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest News
UsernamePublicRestriction

Register

PS048264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel